Once-weekly semaglutide in adults with overweight or obesity
Wilding JPH, Batterham RL, Calanna S, et al. (STEP 1 Study Group) (2021). New England Journal of Medicine.
Summary
A 68-week randomised, double-blind, placebo-controlled trial across 16 countries comparing weekly semaglutide with placebo alongside lifestyle intervention. Reported a mean body-weight change of roughly -15% in the semaglutide group versus about -2% with placebo. Gastrointestinal side effects were the most common adverse events. Industry-funded.